<DOC>
	<DOCNO>NCT00523926</DOCNO>
	<brief_summary>The purpose study assess effect 3 different oral dos TMC207 administer 7 day period organism cause tuberculosis</brief_summary>
	<brief_title>TMC207-C202 : Study Evaluate Bactericidal Activity Multiple Oral Doses TMC207 Subjects With Sputum-Smear Positive Tuberculosis</brief_title>
	<detailed_description>This Phase IIa , open-label , randomize trial treatment-na√Øve , sputum smear-positive , subject pulmonary TB ass extend early bactericidal activity ( eEBA ) TMC207 . The study population consist 60 treatment-naive subject M. tuberculosis infection . Subjects receive orally 25 mg TMC207 po q.d . ( Treatment A ) , 100 mg TMC207 po q.d . ( Treatment B ) 400 mg TMC207 po q.d . ( Treatment C ) daily 7 day . Subjects treatment group D receive 600 mg rifampin po q.d . daily 7 day subject treatment group E receive 300 mg isoniazid po q.d . daily 7 day . After 7 day , subject treatment group receive appropriate anti-TB therapy accord national standard country TB guideline culture sensitivity result sputum specimens clinical microbiological cure achieve . Three once-daily dose regimen TMC207 , 7 day , study versus 2 comparator treatment , rifampin isoniazid present trial.TMC207 treatment group : 25 mg TMC207 po q.d ; 100 mg. TMC207 po q.d ; 400 mg TMC207 po q.d . ; TMC207 administer 10 40 mg/mL oral solution . Comparator group : 600 mg rifampin po q.d . administer capsule contain 300 mg rifampin ; 300 mg isoniazid po q.d . administer tablet contain 300 mg isoniazid .</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Bedaquiline</mesh_term>
	<mesh_term>Diarylquinolines</mesh_term>
	<criteria>Treatmentnaive subject pulmonary M. tuberculosis infection , willing start antiTB therapy Positive acidfast bacillus direct smear exam sputum specimen Must consent HIV testing Must agree hospital admission History presence hepatic GI disease may interfere absorption TMC207 , isoniazid rifampin Subjects receive previous antimycobacterial drug treatment mycobacteria infection subject receive 2 week treatment fluoroquinolone Subjects receive antiretroviral therapy and/or oral I.V . antifungal medication w/in last 90 day Subjects sputum culture M. tuberculosis resistant rifampin Impaired hepatic function</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Tuberculosis</keyword>
</DOC>